Physician profile
Sidra Azim
NPI 1043598378
$2,652.89
in general payments reported to CMS, 2019-2025
24 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $391 · 2021: $13.90 · 2022: $11.71 · 2024: $286 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $706.20 | 2019 | |
| Amgen INC. | $335.37 | 2019-2020 | |
| Dexcom, INC. | $240.41 | 2019-2020 | |
| Abbott Laboratories | $192.32 | 2019-2020 | |
| Novo Nordisk INC | $180.68 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $164.70 | 2019-2024 | |
| Beta Bionics, INC. | $163.68 | 2024 | Ilet Bionic Pancreas |
| Ascendis Pharma Endocrinology INC | $121.82 | 2025 | Yorvipath |
| Lilly USA, LLC | $80.22 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $63.01 | 2019-2020 | |
| Abbvie INC. | $58.57 | 2019-2020 | |
| Medtronic Minimed, INC. | $43.73 | 2019 | |
| Ibsa Pharma INC. | $40.10 | 2019 | |
| Insulet Corporation | $39.61 | 2019 | |
| Merck Sharp & Dohme LLC | $33.07 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $31.34 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $29.08 | 2019 | |
| Corcept Therapeutics | $25.63 | 2020 | |
| Becton, Dickinson and Company | $21.34 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.60 | 2020 | |
| Endo Pharmaceuticals INC. | $19.21 | 2020 | |
| Shire North American Group INC | $15.54 | 2019 | |
| Glaxosmithkline, LLC. | $13.90 | 2021 | |
| Aytu Biopharma, INC. | $12.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sidra Azim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.